Table 1 Reported cases of patients with WM who underwent allo-SCT
Reference | Study type | Patients | GVT (suggested) | Survival | Relapse | TRM |
|---|---|---|---|---|---|---|
Ueda et al.7 | Case report | n=1 (RIC) | Yes (cGVHD) | CR at 5 months | No | No |
Martino et al.8 | Case report | n=2 (MA) | Yes (cGVHD) | PR at 9 years and CR at 3 years | No | No |
Tournilhac et al.3 | Retrospective study | n=10 MA=9 RIC=1 (all heavily pre-treated) | Yes (DLI efficacy) | 60% (3–76 months FU) all in CR | No | 40% (all were in progression) |
Anagnostpoulos et al.5 | Retrospective study | n=3 chemo-resistant (MA=2; RIC=1) | NA | No CR achieved; two MA=death at 1 month and 6 months of GVHD; one RIC died at 24 months | NA | 2/2 (MA) |
Dreger (3rd International Workshop on WM, Paris 2004) | Case reports | n=4 (RIC) heavily pretreated | Yes post-DLI with cGVHD | Three CR achieved | NA | No |
Anagnostopoulos et al.4 | Retrospective study | n=26 50% chemo-resistant MA=21 RIC=5 | NA (high progression rate) | 46% at 3 years (NA data for the RIC subgroup) | 70% at 3 years (NA data for the RIC subgroup) | 40% (NA data for the RIC subgroup) |
